Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377284 | 0.87 | SPHK1 (0.43) | OPRL1SPHK1 | |
| SCHEMBL24736408 | 0.83 | OPRL1 (0.46) | OPRL1KDM4EKMT2A | |
| SCHEMBL14433838 | 0.83 | KDM4E (0.59) | OPRL1KDM4EKMT2ASPHK1 | |
| SCHEMBL24946123 | 0.82 | KDM4E (0.38) | OPRL1KDM4EKMT2AALDH1A1CYP2D6 | |
| SCHEMBL8176923 | 0.82 | POLB (0.39) | POLBKDM4EKMT2AALDH1A1 | |
| SCHEMBL25448438 | 0.81 | OPRL1 (0.46) | OPRL1POLBKDM4EKMT2ASPHK1 | |
| SCHEMBL14418497 | 0.80 | SMN1; SMN2 (0.40) | OPRL1KDM4EKMT2AALDH1A1CYP2D6 | |
| SCHEMBL10027903 | 0.80 | POLB (0.38) | OPRL1POLBKDM4EKMT2AALDH1A1 | |
| SCHEMBL25448432 | 0.78 | OPRL1 (0.41) | OPRL1POLBKDM4EALDH1A1 | |
| SCHEMBL13612612 | 0.78 | MAPT (0.42) | POLBKDM4EKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144411-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC | 2023-05-11 | — | — | US | disclosed |
| US-11365191-B2 | Substituted cyclohexyl compounds as NOP inhibiiors | DART NEUROSCIENCE, LLC (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210340127-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE, LLC | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340127-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | OPRL1, OPRK1, NOP56 | OPRL1 1/4885POLB 360/4885KDM4E 4470/4885 |
| US-11365191-B2 | Substituted cyclohexyl compounds as NOP inhibiiors | OPRL1, OPRK1, GAP43 | OPRL1 1/4885POLB 406/4885KDM4E 4691/4885 |
| US-20230144411-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | OPRL1, OPRK1, NOP56 | OPRL1 1/4885POLB 360/4885KDM4E 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.